Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Sponsor: NRG Oncology
Terminated
Interim monitoring
Other terminated trials from NRG Oncology
Listed as NCT02059265, this PHASE2 trial focuses on Endometrial Clear Cell Adenocarcinoma and Ovarian Clear Cell Cystadenocarcinoma and remains terminated or withdrawn. Sponsored by NRG Oncology, it has been updated 32 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
32 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 27 earlier versions
-
Feb 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Apr 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Suspended PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE2
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NRG Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .